Bailard’s iShares Biotechnology ETF IBB Stock Holding History

Bailard’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Hold	5,462	–	–	0.02%	354
2026 Q1	$922K	Sell	5,462 -101	-2%	-$17.3K	0.02%	334
2025 Q4	$939K	Hold	5,563	–	–	0.02%	329
2025 Q3	$803K	Hold	5,563	–	–	0.02%	375
2025 Q2	$704K	Buy	5,563 +2	+0%	+$246	0.02%	398
2025 Q1	$711K	Buy	5,561 +11	+0.2%	+$1.49K	0.02%	373
2024 Q4	$734K	Sell	5,550 -3	-0.1%	-$422	0.02%	361
2024 Q3	$809K	Hold	5,553	–	–	0.02%	342
2024 Q2	$762K	Sell	5,553 -240	-4%	-$32K	0.02%	341
2024 Q1	$795K	Sell	5,793 -379	-6%	-$51.8K	0.02%	342
2023 Q4	$838K	Hold	6,172	–	–	0.02%	317
2023 Q3	$755K	Sell	6,172 -43	-0.7%	-$5.47K	0.03%	317
2023 Q2	$789K	Sell	6,215 -116	-2%	-$15.1K	0.03%	298
2023 Q1	$818K	Sell	6,331 -398	-6%	-$52.1K	0.03%	296
2022 Q4	$883K	Sell	6,729 -38	-0.6%	-$4.91K	0.03%	279
2022 Q3	$791K	Sell	6,767 -51	-0.7%	-$6.33K	0.03%	271
2022 Q2	$802K	Buy	6,818 +61	+0.9%	+$7.24K	0.03%	273
2022 Q1	$880K	Sell	6,757 -300	-4%	-$39.1K	0.03%	283
2021 Q4	$1.08M	Hold	7,057	–	–	0.03%	254
2021 Q3	$1.14M	Buy	7,057 +177	+3%	+$29.8K	0.04%	251
2021 Q2	$1.13M	Hold	6,880	–	–	0.04%	260
2021 Q1	$1.04M	Buy	6,880 +3,000	+77%	+$477K	0.04%	256
2020 Q4	$588K	Hold	3,880	–	–	0.03%	291
2020 Q3	$525K	Hold	3,880	–	–	0.03%	273
2020 Q2	$530K	Hold	3,880	–	–	0.03%	265
2020 Q1	$418K	Sell	3,880 -472	-11%	-$54.3K	0.03%	256
2019 Q4	$524K	Sell	4,352 -187	-4%	-$20.9K	0.03%	266
2019 Q3	$452K	Hold	4,539	–	–	0.03%	287
2019 Q2	$495K	Buy	4,539 +10	+0.2%	+$1.06K	0.03%	286
2019 Q1	$506K	Hold	4,529	–	–	0.03%	293
2018 Q4	$437K	Sell	4,529 -773	-15%	-$82K	0.03%	327
2018 Q3	$647K	Buy	5,302 +905	+21%	+$107K	0.04%	297
2018 Q2	$483K	Buy	4,397 +145	+3%	+$15.5K	0.03%	375
2018 Q1	$454K	Buy	4,252 +5	+0.1%	+$554	0.03%	339
2017 Q4	$453K	Sell	4,247 -16	-0.4%	-$1.71K	0.03%	323
2017 Q3	$474K	Buy	4,263 +135	+3%	+$14.4K	0.04%	219
2017 Q2	$427K	Buy	4,128 +15	+0.4%	+$1.48K	0.03%	216
2017 Q1	$402K	Buy	4,113 +120	+3%	+$11.5K	0.03%	227
2016 Q4	$353K	Buy	3,993 +1,467	+58%	+$134K	0.03%	230
2016 Q3	$244K	Buy	+2,526	New	+$240K	0.02%	283

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Bailard's IBB Position: Q2 2026 in Review

Bailard held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 5,462 shares worth $1.04M. The position accounts for 0.02% of the portfolio, ranked #354.

Bailard first reported a position in IBB in Q3 2016 and has held it in 40 quarters since. The position peaked at $1.14M in Q3 2021. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Bailard held 5,462 shares of iShares Biotechnology ETF worth $1.04M as of Q2 2026.
Bailard left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.02% of Bailard's portfolio in Q2 2026, its #354 holding.
Bailard first reported a position in iShares Biotechnology ETF in Q3 2016 and has held it in 40 quarters since.
Bailard's iShares Biotechnology ETF position peaked at $1.14M in Q3 2021.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.